Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome

1 minute read

Published: October 6th, 2025

When faced with evolving analysis plans, minimal client infrastructure, and shifting output volumes, Phastar delivered high-quality ISS and ISE outputs for Cushing syndrome clinical studies. 

By combining automation, custom macros, and strategic agility within an FSP model, our team adapted quickly to changing sponsor needs—ensuring consistent quality and on-time delivery despite significant mid-project changes. 

This case study demonstrates how innovation, collaboration, and flexibility can transform complex integration challenges into regulatory-ready solutions that add lasting value for the sponsor. 

Complete the form to download the full case study.

Related articles

Translating Real-World Data into Commercial Success with Outcome Modelling 

Translating Real-World Data into Commercial Success with Outcome Modelling 

July 13th, 2026 1 minute read

Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clini...

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

July 13th, 2026 1 minute read

Biopharma organizations have access to vast amounts of real-world data, but extracting meaningful, actionable insight...

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

July 13th, 2026 1 minute read

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-...